Revlimid has arguably been the single biggest growth driver for Dr Reddy's in recent years, fueling record-high US sales last ...

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1 (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

Sanofi SNY announced that the European Commission (“EC”) has granted marketing authorization to expand the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now ...

Analysts anticipate lower sales of blockbuster cancer drug Revlimid to squeeze Dr Reddy's margins for Q3, thereby dragging ...

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.

Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 billion in sales last year.

Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.

Revlimid (lenalidomide) can cause side effects that range from mild to serious. More common side effects include nausea, fatigue, and anemia. If side effects from Revlimid become difficult to ...

The company also continues to navigate generic competition for its cancer drug Revlimid, which it acquired as part of its 2019 deal for cancer specialist Celgene. However, the drugmaker's ...

Monjuvi, Revlimid, and Rituxan reduced disease progression risk by 57% in relapsed/refractory follicular lymphoma patients compared to placebo plus Revlimid and Rituxan. The investigational regimen ...

Among patients with relapsed or refractory follicular lymphoma (FL), the treatment combination of Monjuvi (tafasitamab-cxix) plus Revlimid (lenalidomide) and Rituxan (rituximab) has been found to ...

The trial evaluated the efficacy and safety of the combination of Incyte’s Monjuvi (tafasitamab), Bristol Myers Squibb’s (BMS’s) Revlimid (lenalidomide), and Biogen’s Rituxan (rituximab ...